Stay updated with breaking news from Bing Kung. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients
IRVINE, Calif.--(BUSINESS WIRE)--Sep 5, 2023--
Place your bets as to what "emerging technology for an unparalleled reading and collecting experience" means for Sean Chen;s Genesis.
- 92% (n=22/24) of Evaluable Patients Achieved Complete Response (CR) at the Initial 3-Month Timepoint from the Phase 2 Clinical Trial of CG0070, an Oncolytic Immunotherapy, in Combination with KEYTRUDA® (pembrolizumab) for NMIBC Unresponsive to BCG -- Promising Preliminary Efficacy and Safety Data from the Phase 1b...
CG Oncology Closes $47 Million Series D Financing IRVINE, Calif.--(Business Wire)--CG Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, today announced the closing of a $47 million Series D preferred stock financing led by new investor Kissei Pharmaceutical Co., Ltd., with participation from existing investors ORI Healthcare Fund, Camford Capital and Perseverance Capital Management. The financing will support the advancement of CG Oncology’s late-stage clinical programs for its lead oncolytic immunotherapy, CG0070, in...